GlobeNewswire Inc.··Zealand PharmaBoehringer's Obesity Drug Survodutide Posts Strong Phase 3 Results, Boosting Zealand Pharma
Boehringer's survodutide shows 16.6% weight loss in Phase 3 trial, benefiting Zealand Pharma with EUR 315M in potential milestone payments and ongoing royalties.
ZLDPYPhase 3 trialweight loss